Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel

Postgraduate Medicine

Volumn 123, Issue 1, 2011, Pages 73-79

  Achar, Suraj ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clopidogrel; Drug interactions; Metabolism; Pharmacokinetics; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 2B9; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DIGOXIN; DRUG METABOLITE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; R 130964; R 138727; RANITIDINE; RIFAMPICIN; UNCLASSIFIED DRUG; WARFARIN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; BLEEDING; BLEEDING TIME; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOGENETICS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; DRUG INTERACTION; HALF LIFE TIME; METABOLIC CLEARANCE RATE;

AREA UNDER CURVE; DRUG INTERACTIONS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 79952802744     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.01.2247     Document Type: Review

References (43)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-e304.
2. Ibanez B, Vilahur G, Badimon JJ. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J Suppl. 2006;8(suppl G):G3-G9.
3. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35(7): 1096-1104.
4. Matsushima N, Jakubowski JA, Asai F, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets. 2006;17(4):218-226.
5. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429-2436.
6. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
7. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 1(8649):1215-1220.
8. Steinhubl SR, Tan WA, Foody JM, Topol E.J. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA. 1999;281(9):806-810.
9. King SB 3rd, Smith SC Jr, Hirshfeld J.W. Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008; 117(2):261-295.
10. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.
11. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109(2):166-171.
12. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J. 2004;25(21):1898-1902.
13. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129(7): 1439-1446.
14. Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol. 2001;132(1):47-54.
15. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Norwalk, CT: Appleton and Lange; 1993.
16. Greenblatt DJ, von Moltke L. Drug-drug interactions. In: Rodrigues AD, ed. Drugs and the Pharmaceutical Sciences. New York, NY: M. Dekker; 2002:xviii, 650.
17. Chang GW, Kam PC. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia. 1999;54(1):42-50.
18. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3): 311-320.
19. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75-85.
20. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72(4):438-452.
21. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25(suppl 2):25-28.
22. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3 A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; 81(5):735-741.
23. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107(1):32-37.
24. Saw J, Steinhubl SR, Berger PB, et al; Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003; 108(8):921-924.
25. Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251-2257.
26. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamicsof prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484.
27. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152(4):627-635.
28. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256-260.
29. Public Health Advisory: Updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). November 17, 2009.
30. Preskorn S. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part 1). Psychopharmacology. 2003;9(2):150-158.
31. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
32. Dumaual C, Miao X, Daly TM, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics. 2007;8(3):293-305.
33. Daly TM, Dumaual CM, Miao X, et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin Chem. 2007;53(7):1222-1230.
34. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirintreated patients with coronary artery disease. Eur Heart J. 2008; 9(1):21-30.
35. Korzonek M, Safranow K, Sulzyc-Bielicka V, Hajduk A. Gastroesophageal reflux disease among patients suffering from coronary artery disease [in Polish]. Ann Acad Med Stetin. 2008;54(2):41-46.
36. Juul-Hansen P, Rydning A. On-demand requirements in patient with endoscopy-negative GERD: H2-blocker versus PPI. Aliment Pharmacol Ther. 2009;29(2):207-212.
37. Liakakos T, Karamanolis G, Patapis P, Misiakos EP. Gastroesophageal reflux disease: medical or surgical treatment? Gastroenterol Res Pract. 2009;2009:371580.
38. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12): 2616-2620.
39. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126-142.
40. Hussar DA. Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride. J Am Pharm Assoc (2003). 2009;49(6):832-836.
41. Plavix (clopidogrel bisulfate) film coated tablet [package insert]. Bristol- Myers Squibb/Sanofi Pharmaceuticals Partnership; Revised 2009.
42. Farid NA, Payne CD, Ernest CS 2nd, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008;48(1):53-59.
43. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77(6):553-559.